化石利胆汤对ERCP术后胆总管结石患者CYP7A1和B-UGT影响研究

Effect of Huashilidan Decoction on CYP7A1、B-UGT in Choledocholithiasis After ERCP

目的:研究化石利胆汤对经逆行胰胆管造影术(Endoscopic Retrograde Cholangiopancreatography,ERCP)取石后的胆总管结石患者血液及胆汁中胆红素尿苷二磷酸葡萄糖醛酸基转移酶(bilirubin UDP-glucronosyltransferase,B-UGT)、胆固醇7α羟化酶(cholesterol 7 alpha-hydroxylase,CYP7A1)的影响。方法:经ERCP证实为胆总管结石并经(Endoscopic sphincterotomy,EST)、机械碎石、网篮球囊取石术等取石后的患者100例,随机分成服药组为常规西医治疗并口服化石利胆汤,对照组为术后只给予常规治疗,每组各50例。服药后第1天、第7天、1个月观察患者血CYP7A1、B-UGT mRNA的表达,及服药后第1天、第7天胆汁中CYP7A1、B-UGT的蛋白表达。结果:实验组服中药后血中CYP7A1、B-UGT mRNA及胆汁中CYP7A1、B-UGT蛋白表达较治疗前明显升高(P<0.05,对照组前后2基因及蛋白表达无变化。结论:化石利胆汤很可能是通过上调CYP7A1、B-UGT的mRNA及蛋白表达,抑制成石性胆汁的形成,从而起到治疗胆结石的作用。

Objective：To explore the effects of Huashilidan decoction on CYP7A1 ,B-UGT in choledocholithiasis after the treatment of ERCP. Method： One hundred patients with cholelithiasis undergoing ERCP and EST, were randomly divided into two groups, the control group and the huashilidan decoction, each group had fifty patients. The patients of control group were treated with the normal anti-inflammatory and rehydration therapy. The other was used with the huashilidan decoction. We scaled the genes shOws of CYP7A1 ,B-UGT in the blood at the first day, the seventh day and the 30th day after the therapy; and scaled CYP7A1, B-UGT in the bile at the first day, the seventh day. Results：After the treatment, CYP7A1 ,B-UGT were greatly higher than those of the experiment group. But those of the control group didn＇ t change. Conclusion ： Huashilidan decoction can reduce the rate., of choledocholithiasis by intervene reglating the expression CYP7A1 ,B-UGT.